Navigation Links
Ambit Biosciences Initiates Two Phase I Clinical Trials
Date:12/20/2010

SAN DIEGO, Dec. 20, 2010 /PRNewswire/ -- Ambit Biosciences (Ambit), today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.

The Phase I trial for AC430 is a two part, placebo-controlled, single ascending, and multiple ascending dose trial in healthy volunteers.  AC430 will be administered orally once-daily and doses escalated until a maximum tolerated or maximum feasible dose is established.  In addition to evaluating the safety, tolerability, and pharmacokinetics of AC430, the study will also assess cytokine signal transduction.  

The Phase I trial for AC480 is a multi-center, dose escalation study with AC480 administered by intravenous infusion on days one and two of a 21 day cycle, either alone or in combination with docetaxel.  The trial will assess safety, pharmacokinetics and anti-tumor activity of AC480 in patients with advanced solid tumors.

"The initiations of these studies are important milestones," said Alan Lewis, President and CEO Ambit Biosciences. "AC430 has demonstrated convincing efficacy in pre-clinical models of autoimmune and inflammatory diseases, and AC480 IV was developed to assess whether pulsatile doses of a pan-HER inhibitor administered in combination with a taxane such as docetaxal would produce synergistic anti-tumor activity."

About AC430AC430 was specifically developed to be a best-in-class JAK2 inhibitor.  In preclinical studies, AC430 has exhibited potency against JAK2 in cell-based models that is at least equivalent, and in most cases superior to, competing JAK2 inhibitors, and also has excellent oral pharmacokinetic properties.  In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg/kg/day.  JAK2 has been implicated as a target for therapy in both oncology and autoimmune disease
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ambit Biosciences Strengthens Board of Directors and Executive Team
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
4. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
5. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
6. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
7. Cell Biosciences Announces US Patent Issuance
8. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
9. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
10. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Cynosure, Inc. (Nasdaq: CYNO ), ... systems for high-volume applications, today reported financial results for ... financial results incorporate the acquisition of Palomar Medical Technologies, ... Second-Quarter 2014 Financial Highlights ... , Non-GAAP net income of $7.1 million, or $0.32 ...
(Date:7/29/2014)... --   What:   AFFiRiS AG, ... from a Phase I clinical trial of PD01A, a ... disease progression. The Michael J. Fox Foundation supported the ... the impact of the results for patients and the ... 2014         11.00 am ...
(Date:7/29/2014)... 2014  Drug development for hepatitis C virus ... and the intense need for curative therapy in ... underway as the market moves away from protease ... interferon-free oral therapies. Logo - ... blockbuster Sovaldi is the first of these novel ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
(Date:7/29/2014)... -- Want young children to embrace a more healthful ... good for them. Doing so will actually make them ... "Parents and caregivers who are struggling to get ... serving the food without saying anything about it, or ... said study authors Michal Maimaran, of Northwestern University,s Kellogg ...
(Date:7/29/2014)... Randy Dotinga HealthDay Reporter ... most children take on a task, various brain connections ... activity in kids with autism, according to a small ... of autism displayed even less of this "brain flexibility," ... often causes difficulty when children with autism are faced ...
(Date:7/29/2014)... CA (PRWEB) July 29, 2014 According ... website of Time Magazine titled “From Kim’s Butt to ... Kim Kardashian’s butt is the celebrity feature most ... their features include Beyoncé’s butt, Jennifer Lawrence’s ... This information is based on data collected by an ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Many people complain ... thing they do each morning is put on glasses to ... These same individuals also may be dissatisfied with their ... , Cataracts may cause difficulty driving, especially at night ... follow or find one’s golf ball, see the TV, sew ...
(Date:7/29/2014)... Alan Mozes HealthDay Reporter ... autism patients with just a single dose of the hormone ... emotions, Japanese researchers report. Known as the "love hormone," ... bonding between lovers, and between mothers and their children. ... key area of the brain that has long been associated ...
Breaking Medicine News(10 mins):Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3
... estimated that as,many as 40 percent of all people ... of all children with lupus, will develop kidney,complications that ... Kidney Month and the Lupus Foundation of America,(LFA) is ... and,potentially life-threatening complication of lupus. The LFA will conduct ...
... guideline on colorectal cancer screening released today by ... health care organizations, including the American College of ... (ASGE) and the American Cancer Society (ACS), offers ... and states a strong preference for screening tests ...
... 6 Pregis Corporation, a leading,international manufacturer, ... specialty packaging solutions, will conduct an investor,conference ... and full year results on,Thursday, March 20, ... CT). The call can be,accessed through the ...
... ARLINGTON, Va., March 6 Champions,Biotechnology, Inc. (OTC Bulletin ... third quarter financial results.,Full details of the Company,s financial ... http://www.sec.gov , For the three months ended January ... earnings per share of $0.02 compared to a net ...
... up 23%, Adjusted EBITDA up 33%, TORONTO, March ... leading provider of products and services to the global ... For the,quarter, MDS reported net revenues of $296 million, ... continuing operations of $0.14.,Adjusted EBITDA rose to $40 million, ...
... The Board of Directors of Essilor International, the world leader in,ophthalmic optical products, today announced its audited financial results,for the ... 2007 ... 2,908.1 ... 482.6 + 9.3%, As a % of revenue ...
Cached Medicine News:Health News:Lupus Foundation of America Webchat to Discuss Kidney Disease in Lupus 2Health News:New guidelines update recommendations on colorectal cancer screening 2Health News:New guidelines update recommendations on colorectal cancer screening 3Health News:New guidelines update recommendations on colorectal cancer screening 4Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 2Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 3Health News:MDS Reports First Quarter 2008 Results 2Health News:MDS Reports First Quarter 2008 Results 3Health News:MDS Reports First Quarter 2008 Results 4Health News:MDS Reports First Quarter 2008 Results 5Health News:MDS Reports First Quarter 2008 Results 6Health News:MDS Reports First Quarter 2008 Results 7Health News:MDS Reports First Quarter 2008 Results 8Health News:MDS Reports First Quarter 2008 Results 9Health News:MDS Reports First Quarter 2008 Results 10Health News:MDS Reports First Quarter 2008 Results 11Health News:MDS Reports First Quarter 2008 Results 12Health News:MDS Reports First Quarter 2008 Results 13Health News:MDS Reports First Quarter 2008 Results 14Health News:MDS Reports First Quarter 2008 Results 15Health News:MDS Reports First Quarter 2008 Results 16Health News:MDS Reports First Quarter 2008 Results 17Health News:MDS Reports First Quarter 2008 Results 18Health News:MDS Reports First Quarter 2008 Results 19Health News:MDS Reports First Quarter 2008 Results 20Health News:MDS Reports First Quarter 2008 Results 21Health News:MDS Reports First Quarter 2008 Results 22Health News:MDS Reports First Quarter 2008 Results 23Health News:MDS Reports First Quarter 2008 Results 24Health News:MDS Reports First Quarter 2008 Results 25Health News:MDS Reports First Quarter 2008 Results 26Health News:MDS Reports First Quarter 2008 Results 27Health News:MDS Reports First Quarter 2008 Results 28Health News:MDS Reports First Quarter 2008 Results 29Health News:MDS Reports First Quarter 2008 Results 30
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
Medicine Products: